Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.

Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis : our experience of efficacy / S. Ferrucci, S. Tavecchio, E. Berti, L. Angileri. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2019 Sep 02). [Epub ahead of print] [10.1080/09546634.2019.1659479]

Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis : our experience of efficacy

S. Tavecchio;E. Berti;L. Angileri
2019

Abstract

Background: Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype. Case Report: Here, we described 11 patients with PN-like AD treated with dupilumab, a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, at first and fourth month after starting treatment. We collected different scores such as NRSi as well as IGA. At the same time, patient subjective benefits were analyzed through DLQI, POEM, and HADS scores. Quality of sleep was also recorded by NRSS. All patients showed rapid clinical improvement of cutaneous lesions and no other new lesions were reported during treatment. Reduction of daily itching was referred already after the first month of treatment. Conclusion: These results show the effectiveness of dupilumab in this clinical setting of AD, supporting this treatment as a valid therapeutic approach in difficult-to-treat-PN-like clinical presentation of AD.
atopic dermatitis; dupilumab; Prurigo nodularis
Settore MED/35 - Malattie Cutanee e Veneree
2-set-2019
2-set-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dupilumab and prurigo nodularis like phenotype in atopic dermatitis our experience of efficacy (1).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 658.42 kB
Formato Adobe PDF
658.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/722783
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 30
social impact